In preclinical models of myeloproliferative diseases, TG101348, administered orally, was shown to reduce V617F expressing cell populations in a dose-dependant manner without adversely impacting normal hematopoeisis. The reduction of V617F-expressing cell populations correlated with improved survival and reduced morbidity.
The V617F mutation of JAK2 is implicated in the pathogenesis of certain myeloproliferative diseases, including polycythemia vera, essential thrombocytopenia and primary myelofibrosis.